Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

733.29 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Nasdaq, Dow Jones Futures Rise On Meta, Microsoft Results: Apple Earnings Loom, Analyst Doubts New Bull Run For Stock Markets
Notwithstanding the recent seven-session run, the S&P 500 Index ended April — a historically strong month — with a loss of 0.8%. 
Via Stocktwits
Topics Economy Stocks World Trade
Exposures Fossil Fuels Interest Rates Tariff
New Weight Loss Pill & Massive U.S. Investment Sends Eli Lilly Stock Soaring – Is It Too Late To Buy?
Eli Lilly, a pharmaceutical leader in obesity and diabetes treatment, is back in the spotlight, and for good reason. 
Via Talk Markets
Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?
Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in past year. 
Via Benzinga
Price Over Earnings Overview: Eli Lilly
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Via The Motley Fool
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Via The Motley Fool
What To Expect From Eli Lilly’s (LLY) Q1 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
WeightWatchers Stock Rockets After Partnership For Eli Lilly's Zepbound Drug: Retail Investors Very Optimistic
Eligible self-pay patients without insurance can now access prescriptions for Zepbound in single-dose vial form through the WeightWatchers app. 
Via Stocktwits
Topics Bankruptcy
Exposures Financial Legal
Why Is WeightWatchers (WW) Stock Soaring Today
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum
Eli Lilly (LLY) will report Q1 results on Thursday. Analysts expect in line results with focus on tirizepatide and obesity franchise. 
Via Benzinga
Why Viking Therapeutics Stock Popped Again Today
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock. 
Via The Motley Fool
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy. 
Via Benzinga
WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%
WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli Lilly's LillyDirect pharmacy provider. 
Via Benzinga
The S&P 500 Is Doing Something That Hasn't Been Seen in Nearly 100 Years. Here Are the 10 Most Important Stocks to Keep an Eye On.
Concentration levels in the S&P 500 are at their highest levels since 1932. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
WeightWatchers Bankruptcy Buzz Could Be A Strategy To 'Get A Better Deal With The Bonds,' Says Activist Investor
Galloway Capital, which owns a 2.87% stake, says WeightWatchers should avoid bankruptcy. 
Via Stocktwits
Topics Bankruptcy
Exposures Financial Legal
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
Why AbbVie Stock Trounced the Market Today
Via The Motley Fool
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Why Viking Therapeutics Stock Popped Today
2025 is the year we learn whether Viking Therapeutics stock will be a winner. 
Via The Motley Fool
Eli Lilly Stock Gets A Double Downgrade And Price Target Cut By HSBC Over Valuation, Competition Concerns
HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in light of potential economic sensitivity to the adoption curve for weight loss... 
Via Stocktwits
Topics Lawsuit
Exposures Financial Legal
IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval
The company says a new process will improve its output by 20%, benefitting revenue and earnings later this year. 
Via Investor's Business Daily
Exposures Product Safety
3 Volatile Stocks with Questionable Fundamentals
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
This Eli Lilly Analyst Turns Bearish; Here Are Top 4 Downgrades For Monday
Via Benzinga
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023. 
Via Stocktwits
Exposures Product Safety
Pfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 Print
Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its... 
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Cramer's Warning: Tariff Chaos Could Derail Tech Earnings Frenzy This Week
Jim Cramer is preparing investors for another action-packed week on Wall Street, packed with earnings reports from major tech players and key economic updates. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.